Annexon reported rapid, clinically meaningful improvement in strength and reduced disability within days in the first 10 U.S. and European FORWARD GBS patients treated with tanruprubart.
Key Highlights:
- All 10 patients showed rapid, clinically meaningful muscle-strength improvement within four days of a single 30 mg/kg infusion.
- Four bedbound patients walked (with or without assistance) between day 2 and day 8; one ventilated patient was off ventilator within four days.
- Five additional patients showed marked functional gains within 48 hours, reinforcing consistency with prior Phase 3 and real-world findings.
- Tanruprubart was generally well-tolerated; adverse events were mostly related to GBS or disease complications and consistent with Phase 3.
- FORWARD data are planned to support a BLA submission targeted for Q4 2026; tanruprubart is under EMA review.
Original SEC Filing:
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.